End of AIDS on the horizon, but innovation needed to end HIV

The Lancet HIV

Volumn 2, Issue 3, 2015, Pages e74-e75

  Vella, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL RESEARCH; EPIDEMIC; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LOWEST INCOME GROUP; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT FAILURE; VIRUS LOAD; VIRUS TRANSMISSION; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE COURSE; DISEASE TRANSMISSION; HEALTH PROGRAM; MORBIDITY; MORTALITY; PATIENT CARE; PUBLIC HEALTH; ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 84925423127     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00023-5     Document Type: Note

References (13)

1. Lima VD, Lourenço L, Yip B, Hogg RS, Phillips P, Montaner JSG AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. The Lancet HIV 2015, published online Feb 13. http://dx.doi.org/10.1016/S2352-3018(15)00017-X.
2. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013, 8:e81355.
3. Global report: UNAIDS report on the global AIDS epidemic 2013 [Online] 2013, Joint United Nations Programme on HIV/AIDS (UNAIDS), UNAIDS, Geneva, (accessed Feb 9, 2015). http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.
4. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection WHO, (accessed Feb 9, 2015). http://www.who.int/hiv/pub/guidelines/arv2013/download/en/.
5. Murray CJL, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:1005-1070.
6. Lessells RJ, Mutevedzi PC, Iwuji CC, Newell ML Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr 2014, 65:e1724.
7. Ying R, Barnabas RV, Williams BG Modeling the implementation of universal coverage for hiv treatment as prevention and its impact on the hiv epidemic. Current HIV/AIDS Reports 2014, 11:459-467.
8. Nosyk B, Montaner JS, Colley G, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet infect Dis 2014, 14:40-49.
9. HIV prevention: progress to date US Centres for Diseases Control and Prevention, (accessed Feb 9, 2015). http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/Progress-508.pdf.
10. Paton NI, Kityo C, Hoppe A, et al. Assessment of secondline antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014, 371:234-247.
11. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2014, 381:2091-2099. SECONDLINE Study Group.
12. Fauci AS, Folkers GK, Dieffenbach CW HIV-AIDS: much accomplished, much to do. Nat Immunol 2013, 14:1104-1107.
13. Murray CJ Maximizing antiretroviral therapy in developing countries: the dual challenge of efficiency and quality. JAMA 2015, 313:359-360.